

Table of Contents

<i>CERTIFICATE</i>	<i>iii</i>
<i>CERTIFICATE</i>	<i>iv</i>
<i>CERTIFICATE</i>	<i>v</i>
<i>Declaration</i>	<i>vi</i>
<i>Preface</i>	<i>vii</i>
<i>ACKNOWLEDGEMENTS</i>	<i>ix</i>
<i>List of Tables</i>	<i>xi</i>
<i>List of Figures</i>	<i>xii</i>
<i>List of Scheme</i>	<i>xxii</i>
<i>List of Abbreviations</i>	<i>xxiii</i>
CHAPTER I	1
1. Introduction and Objective	1
1.1. Kinases	1
1.2. Bruton's Tyrosine Kinase (BTK)	3
1.2.1. PH domain.....	4
1.2.2. TH domain.....	5
1.2.3. SH3 domain.....	5
1.2.4. SH2 domain.....	5
1.2.5. Catalytic domain.....	6
1.3. B cell receptor signalling	6
1.3.1. B cell/lymphocyte	6
1.3.2. Role of BTK in B cell receptor (BCR) signalling	10

1.3.3. BTK in other signalling pathway	12
1.4. B cell malignancies/ lymphomas	14
1.4.1. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)	15
1.4.2. Follicular lymphoma (FL)	16
1.4.3. Mantle cell lymphoma (MCL)	16
1.4.4. Marginal zone lymphomas (MZL).....	17
1.4.5. Lymphoplasmacytic lymphoma/ Waldenström macroglobulinemia (WM)	17
1.4.6. Burkitt lymphoma (BL).....	18
1.4.7. Diffuse large B-cell lymphoma (DLBCL)	19
1.4.8. Hairy cell leukemia (HCL)	19
1.5. Rheumatoid Arthritis (RA)	20
1.6. Therapeutic treatments for Rheumatoid arthritis (RA).....	21
1.6.1. Non-steroidal anti-inflammatory agents (NSAIDs)	22
1.6.2. Corticosteroids	22
1.6.3. Disease-modifying anti-rheumatic drugs (DMARDs).....	23
1.6.4. Biologic agents	23
1.6.5. Kinase inhibitors.....	23
1.7. Therapeutic treatments for B cell lymphoma (BCL)	24
1.7.1. Chemotherapy.....	24
1.7.2. Immunotherapy	24
1.7.3. Stem cell transplant	25
1.7.4. Targeted Therapy	25
1.7.5. Checkpoint inhibitors	26
1.7.6. B-cell receptor pathway inhibitors	26
1.7.7. Proteasome inhibitors.....	26
1.7.8. Immunomodulators	27
1.7.9. HDAC inhibitors	27
1.8. BTK inhibitor	28

1.8.1. BTK inhibitors in preclinical and clinical development	29
1.9. Objectives.....	33
CHAPTER 2	34
2. Results and Discussion	34
2.1. Design strategy	34
2.2. 3-(4-phenoxyphenyl)-pyrazolo[3,4-d]pyrimidin-4-amine scaffold based BTK inhibitors 24a-h (Series 1)	37
2.2.1. Chemistry	37
2.2.2. Biological evaluation of Series 1	41
2.2.3. Molecular docking study of 24e of Series 1	45
2.3. 1-(octahydrocyclopenta[c]pyrrol-5-yl)-1H-pyrazolo[3,4- d]pyrimidin-4-amine scaffold based BTK inhibitors 32a-an (Series 2)	46
2.3.1. Chemistry	46
2.3.2. Biological evaluation of Series 2	50
2.3.3. Molecular docking study of 32b of Series 2	56
2.4. 4-(4-amino-1-(octahydrocyclopenta[c]pyrrol-5-yl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)-N-(pyridin-2-yl)benzamide scaffold based BTK inhibitors 32ao-av (Series 3)	58
2.4.1. Chemistry	58
2.4.2. Biological evaluation of Series 3	59
2.4.3. Molecular docking study of 32ao of Series 3	62
2.5. BTK inhibitors (41, 42, 51, 52, 61, 62, 71, and 72) based on pyrazolo- pyrimidin-4-amine scaffold's mimetic aromatic heterocycles (Series 4)	64
2.5.1. Chemistry	64
2.5.2. Biological evaluation of Series 4	69

2.6. Developmental studies of 32b	71
2.6.1. Physicochemical characteristics of 32b	72
2.6.2. ADME profile of 32b	73
2.6.3. <i>In vivo</i> efficacy studies of 32b.....	73
2.6.4. Irreversible (covalent) binding of 32b to the BTK enzyme	78
2.6.5. Kinase selectivity of 32b	80
2.6.6. Safety profile of 32b	81
CHAPTER 3	86
3. Summery, Conclusion, and Way Forward	86
CHAPTER 4	90
4. Experimental	90
4.1. Chemistry	90
4.1.1. Preparation of tert-butyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)- carboxylate (Intermediate 6e).	91
4.1.2. Preparation of tert-butyl 6-hydroxyoctahydro-2H-cyclopenta[c]pyridine-2- carboxylate (Intermediate 6g).	95
4.1.3. Preparation of tert-butyl (7R,8aS)-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine- 2(1H)-carboxylate (Intermediate 6h).	98
4.1.4. Preparation of compounds 24a-h of Series 1	103
4.1.5. Preparation of (4-(pyridin-2-ylcarbamoyl)phenyl)boronic acid (Intermediate 28b).	115
4.1.6. Preparation of compounds 32a-an of Series 2	117
4.1.7. Preparation of compound 32ao-av Series 3	159
4.1.8. Preparation of compound 41 and 42 of Series 4.....	168
4.1.9. Preparation of compound 51 and 52 of Series 4.....	176
4.1.10. Preparation of compound 61 and 62 of Series 4.....	183
4.1.11. Preparation of compound 71 and 72 of Series 4.....	191

4.2. Biology	198
4.2.1. BTK enzyme inhibition assay and kinase selectivity assay.....	198
4.2.2. TMD8 cell anti proliferation assay	198
4.2.3. CYP inhibition assay	199
4.2.4. hERG inhibition assay.....	199
4.2.5. Pharmacokinetic studies	199
4.2.6. <i>In vivo</i> efficacy studies.....	200
4.2.7. Caco-2 permeability assay.....	201
4.2.8. Liver microsome stability assay.....	202
4.2.9. Plasma protein binding	202
4.2.10. Acute toxicity studies.....	202
4.2.11. Molecular docking protocol.....	205
 CHAPTER 5	 206
 5. Spectral Data.....	 206
 CHAPTER 6	 290
 6. References.....	 290
 CHAPTER 7	 307
 7. Publication and Posters	 307